Cis-Diamminedichloroplatinum Ii
Adrenal Cortex Carcinoma
Explore 21 assets in Adrenal Cortex Carcinoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Vanderbilt-Ingram Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02831179CT.gov Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | — | Withdrawn | — | — | — |
NCT01833832CT.gov Surgery and Heated Chemotherapy for Adrenocortical Carcinoma | — | Completed | — | — | — |
NCT00436657CT.gov Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adrenal Cortex Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Vanderbilt-Ingram Cancer Center | P2 | BB · 66 |
| Adriamycin | National Cancer Institute (NCI) | P2 | BB |
| Pembrolizumab | Corcept Therapeutics | P2 | B |
| Cyclophosphamide | Anusha Kalbasi | P2 | B |
| Nivolumab | Dana-Farber Cancer Institute | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Sodium Thiosulfate | National Cancer Institute (NCI) | P2 | B |
| Tamoxifen | Ottawa Regional Cancer Centre | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | CCC |
+34 more in the Adrenal Cortex Carcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Adrenal Cortex Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-adrenal-cortex-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →